The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.

[1]  M. Pegram,et al.  Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer , 2016, Tumor Biology.

[2]  Yunfeng Zhou,et al.  Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. , 2015, Molecular and clinical oncology.

[3]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Iezzi,et al.  Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. , 2014, Biochemical pharmacology.

[5]  W. Berger,et al.  NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application , 2014 .

[6]  U. Rothlisberger,et al.  Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity , 2014, Nature Communications.

[7]  C. Andreani,et al.  Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. , 2014, Cellular signalling.

[8]  S. Ferraro,et al.  Essential trace elements in milk and blood serum of lactating donkeys as affected by lactation stage and dietary supplementation with trace elements. , 2013, Animal : an international journal of animal bioscience.

[9]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[10]  Nicolas P E Barry,et al.  Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.

[11]  Francesca Orso,et al.  p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells , 2012, Breast Cancer Research.

[12]  K. Khazaie,et al.  Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration , 2012, PloS one.

[13]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[14]  P. Sadler,et al.  Designing organometallic compounds for catalysis and therapy. , 2012, Chemical communications.

[15]  F. Bertucci,et al.  Basal Breast Cancer: A Complex and Deadly Molecular Subtype , 2012, Current molecular medicine.

[16]  Gregory S. Smith,et al.  Targeted and multifunctional arene ruthenium chemotherapeutics. , 2011, Dalton transactions.

[17]  P. Dyson,et al.  Metal-based antitumour drugs in the post-genomic era: what comes next? , 2011, Dalton transactions.

[18]  J. Schlom,et al.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity , 2011, Experimental biology and medicine.

[19]  A. Sbarbati,et al.  Mesenchymal/Stromal Gene Expression Signature Relates to Basal-Like Breast Cancers, Identifies Bone Metastasis and Predicts Resistance to Therapies , 2010, PloS one.

[20]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[21]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[22]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[23]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Muggia.  BRCA-deficient animal models and cisplatin resistance. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Anna F. A. Peacock,et al.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.

[26]  C. Pettinari,et al.  Synthesis and intramolecular and interionic structural characterization of half-sandwich (arene)ruthenium(II) derivatives of bis(pyrazolyl)alkanes. , 2008, Inorganic chemistry.

[27]  K. Mokbel,et al.  The role of cyclooxygenase-2 in breast cancer: review , 2008, Breast Cancer Research and Treatment.

[28]  A. Sbarbati,et al.  Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice , 2008, Oncogene.

[29]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[30]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[31]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[32]  R. Palmqvist,et al.  High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer , 2007, Clinical Cancer Research.

[33]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Duarte,et al.  Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. , 2006, Toxicology.

[35]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[36]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Sbarbati,et al.  Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells. , 2005, Carcinogenesis.

[38]  Di Chen,et al.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells , 2005, Breast Cancer Research.

[39]  P. Dyson,et al.  In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.

[40]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[41]  T. Ley,et al.  Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. , 2004, Blood.

[42]  A. Bergamo,et al.  Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.

[43]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[44]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[45]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[46]  B. Pockaj,et al.  Reduced T-Cell and Dendritic Cell Function Is Related to Cyclooxygenase-2 Overexpression and Prostaglandin E2 Secretion in Patients With Breast Cancer , 2004, Annals of Surgical Oncology.

[47]  J. Cummings,et al.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.

[48]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  M. Piccart,et al.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[51]  J. Albina,et al.  Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. , 1994, Cancer research.

[52]  G. Sava,et al.  Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse , 1994, Clinical & Experimental Metastasis.

[53]  S. Edwards,et al.  Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. , 1993, Journal of immunology.

[54]  A. Casini,et al.  Organometallic Antitumour Agents with Alternative Modes of Action , 2010 .

[55]  F. Muggia.  Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. , 2009, Gynecologic oncology.

[56]  A. Bergamo,et al.  Ruthenium anticancer drugs. , 2004, Metal ions in biological systems.